ABBOTINDIA
Abbott India share price & financials
- Price
- ₹28,055
- Market cap
- ₹54.3k Cr
- Sector
- Healthcare
What Abbott India Limited does
Abbott India Limited is the Indian pharmaceutical subsidiary of global healthcare group Abbott Laboratories, engaged in the development, manufacture and marketing of branded generic medicines, vaccines and nutritional/wellness products. It earns through sale of these branded products via trade channels and institutions, promoted to doctors and healthcare professionals by its own field sales force. The company covers six therapy areas — Gastroenterology, Women's Health, Metabolics, Central Nervous System (CNS), Vaccines and Multi-Specialty — and manufactures a portion of its products at its own facility in Goa, sourcing the rest from third-party manufacturers and group affiliates.
Segments
- Gastroenterology
- Women's Health
- Metabolics
- Central Nervous System (CNS)
- Vaccines
- Multi-Specialty
- Products in portfolio
- 130+
- Brands ranked #1 or #2 in their respective participated markets
- 16
- Brands in Top 100 of Indian Pharmaceutical Market (IPM)
- 8
- Brands in Top 300 of IPM
- 10
- New products launched in FY 2024-25
- 7
- Own manufacturing facility
- Goa plant
Quarterly results
Q1 FY27: revenue up 4.4%, net profit up 17.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 +8% | 1,724 +7% | 1,710 +7% | 1,814 +4% |
| EBITDA | 439 | 436 | 429 | 446 | 502 +14% | 463 +6% | 481 +12% | 522 +17% |
| Net profit | 359 | 361 | 367 | 366 | 415 +16% | 376 +4% | 395 +8% | 429 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −18.3% 1Y
1Y: ₹31,255 on 10 Sept 2025 → ₹25,550. High ₹31,255 (10 Sept 2025), low ₹25,180 (24 Apr 2026).
Financials, as filed
Revenue grew 9.0% a year over 3 years, FY23 to FY26. Operating margin widened to 27.3%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹5.3k Cr | ₹5.8k Cr | ₹6.4k Cr | ₹6.9k Cr |
| Operating profit | ₹1.2k Cr | ₹1.5k Cr | ₹1.7k Cr | ₹1.9k Cr |
| Operating margin | 22.5% | 24.9% | 26.4% | 27.3% |
| Interest | ₹16 Cr | ₹12 Cr | ₹11 Cr | ₹25 Cr |
| Depreciation | ₹69 Cr | ₹71 Cr | ₹72 Cr | ₹76 Cr |
| Net profit | ₹950 Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.6k Cr |
| Net margin | 17.8% | 20.5% | 22.1% | 22.4% |
| Cash from operations | ₹893 Cr | ₹1.2k Cr | ₹1.0k Cr | ₹1.3k Cr |
| Free cash flow | ₹860 Cr | ₹1.2k Cr | ₹960 Cr | ₹1.3k Cr |
| ROCE | 41.0% | 46.0% | 46.0% | 45.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr |
| Reserves | ₹2.6k Cr | ₹2.8k Cr | ₹3.2k Cr | ₹3.7k Cr | ₹4.0k Cr | ₹4.8k Cr |
| Borrowings | ₹153 Cr | ₹152 Cr | ₹113 Cr | ₹83 Cr | ₹182 Cr | ₹172 Cr |
| Other liabilities | ₹1.1k Cr | ₹1.3k Cr | ₹1.3k Cr | ₹1.4k Cr | ₹1.5k Cr | ₹1.6k Cr |
| Total liabilities | ₹3.8k Cr | ₹4.2k Cr | ₹4.6k Cr | ₹5.2k Cr | ₹5.7k Cr | ₹6.5k Cr |
| Fixed assets | ₹251 Cr | ₹271 Cr | ₹237 Cr | ₹225 Cr | ₹314 Cr | ₹331 Cr |
| Capital work in progress | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹10 Cr | ₹23 Cr | ₹6 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹3.6k Cr | ₹4.0k Cr | ₹4.3k Cr | ₹5.0k Cr | ₹5.4k Cr | ₹6.2k Cr |
| Total assets | ₹3.8k Cr | ₹4.2k Cr | ₹4.6k Cr | ₹5.2k Cr | ₹5.7k Cr | ₹6.5k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs trimmed −0.41 pp while FIIs added +0.22 pp. The shareholder count grew 16% to 78,320.
- Promoters
- 75.0%
- FIIs
- 0.4%
- DIIs
- 8.8%
- Public
- 15.8%
Since Jun 2025
- DIIs −0.41 pp
- FIIs +0.22 pp
- Public +0.18 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 0.2%, DIIs 8.8%, Public 16.0%.Dec '23: Promoters 75.0%, FIIs 0.2%, DIIs 8.7%, Public 16.1%.Mar '24: Promoters 75.0%, FIIs 0.2%, DIIs 8.9%, Public 15.9%.Jun '24: Promoters 75.0%, FIIs 0.2%, DIIs 8.8%, Public 16.0%.Sep '24: Promoters 75.0%, FIIs 0.2%, DIIs 9.0%, Public 15.9%.Dec '24: Promoters 75.0%, FIIs 0.2%, DIIs 9.0%, Public 15.8%.Mar '25: Promoters 75.0%, FIIs 0.2%, DIIs 8.9%, Public 15.9%.Jun '25: Promoters 75.0%, FIIs 0.2%, DIIs 9.2%, Public 15.7%.Sep '25: Promoters 75.0%, FIIs 0.2%, DIIs 9.1%, Public 15.7%.Dec '25: Promoters 75.0%, FIIs 0.2%, DIIs 9.0%, Public 15.8%.Mar '26: Promoters 75.0%, FIIs 0.3%, DIIs 8.9%, Public 15.8%.Jun '26: Promoters 75.0%, FIIs 0.4%, DIIs 8.8%, Public 15.8%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Nippon Life India Trustee Ltd Mutual fund newly disclosed 1.07% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Abbott India Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Abbott Capital India Limited | 50.44% | unchanged |
| Abbott Healthcare Products Limited | 17.62% | unchanged |
| British Colloids Limited | 6.92% | unchanged |
| SBI Nifty Midcap 150 Momentum 50 ETF Mutual fund | 1.92% | −0.24 pp |
| Canara Robeco Mutual Fund Mutual fund | 1.07% | unchanged |
| Nippon Life India Trustee Ltd Mutual fund | 1.07% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ABBOTINDIA
Filings to Aug 2026
0 new, 7 added, 3 trimmed, 1 sold out — net −0.37 L shares (−5.7%).
- Held by funds
- ₹1.6k Cr
- 14 schemes
- Biggest holder
- SBI Large and Midcap Fund
- ₹796 Cr · 1.9% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| SBI Large and Midcap Fund SBI Mutual Fund | ₹796 Cr | held | Sep '22 |
| Nippon India Multi Cap Fund Nippon India Mutual Fund | ₹379 Cr | +0.20 L | Oct '21 |
| Nippon India Pharma Fund Nippon India Mutual Fund | ₹202 Cr | +0.03 L | Sep '12 |
| Nippon India Vision Large & Mid Cap Fund Nippon India Mutual Fund | ₹69 Cr | held | Jul '26 |
| SBI MNC Fund SBI Mutual Fund | ₹25 Cr | −0.14 L | Aug '21 |
| Nippon India Retirement Fund - Wealth Creation Scheme Nippon India Mutual Fund | ₹25 Cr | held | Jun '24 |
| Nippon India Nifty Pharma ETF Nippon India Mutual Fund | ₹23 Cr | +0.00 L | Sep '21 |
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹20 Cr | −0.12 L | Aug '21 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
7 added, 3 trimmed — net −36,972 shares (−5.7%)
- Funds are sitting on
- +18%
- vs est. average cost
- Held by funds
- ₹1.6k Cr
- 14 schemes · ≈ 3.1% of the company
- Biggest holder
- SBI Large and Midcap Fund
- ₹796 Cr · 1.9% of that fund
- Longest holder
- Nippon India Pharma Fund
- 14y · since Sep '12
Shares held by these funds +36%
Aug '23 6.43 L shares Jul '26
What the price assumes
ExpensiveTo justify its price of ₹25550, this stock must grow earnings at 24% every year for 7 years. Our analysis caps realistic growth at ~18%. At that growth it is worth ₹18981 — downside of 26%.
- Growth the price implies
- 23.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 17.8% a year
- net profit, FY23–FY26 · EPS 17.8%
- The gap
- 0.1 pp
- -26% downside if it only repeats history
Learn to analyse Abbott India Limited
Guides on how to read this kind of business and the numbers that matter.